Veracyte is adding urologic cancer tests to its genomics testing portfolio with the acquisition of Decipher Biosciences.
Veracyte acquired Decipher for $600m in cash, the companies announced on 15 March
Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.
